← Leaderboards
Lucie Marie Turcotte
University Of Minnesota
$1,777,930
Attributed
$2,841,722
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $676.5K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,841,722 · 3
By mechanism
R01$2,127,584 · 2
K08$714,138 · 1
Top collaborators
- Jennifer Mary Knight5 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Laura Jane Niedernhofer$20,513,980
- Daniel A. Mulrooney$2,717,970
- Edgar A Arriaga$9,497,757
- Chetan N Shenoy$2,628,221
- Beshay Zordoky$3,176,408
Others in their field
Other Emerging Leaders on “High Risk”
- Chanza Baytop · Westat, Inc.$271,217,917
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Ted Ross · University Of Georgia$70,992,558
- Yunda Huang · Fred Hutchinson Cancer Center$69,424,989
- Bambra Strokes · Ppd Development Lp$65,000,267
- Susan Abushakra · Alzheon, Inc.$47,265,244
Research focus
High RiskDisease-Free SurvivalInferiorCharacteristicsRaceMalignant NeoplasmsImproved OutcomeResponseMorbidity - Disease RateResearch PersonnelRisk FactorsCancer TherapyFollow-UpMortalityComorbidityMortality RiskCohortLeukemiaExposure ToCancer SurvivorCancer Health DisparityEffective InterventionEngraftmentFoundations
Grant awards (9)
Socioeconomic and adversity-associated immunobiologic influences on pediatric hematopoietic cell transplant outcomes$676,550
R01 · FY2025 · CA · contact PI
(PQ2) Donor socioeconomic status as a predictor of altered immune function and treatment response following hematopoietic cell transplantation for hematologic malignancy$346,962
R01 · FY2022 · CA
(PQ2) Donor socioeconomic status as a predictor of altered immune function and treatment response following hematopoietic cell transplantation for hematologic malignancy$354,037
R01 · FY2021 · CA
Treatment Modifications, Outcomes and Provider Decision Making in the Management of Subsequent Breast Cancers Among Survivors of Childhood Cancer$178,354
K08 · FY2021 · CA · contact PI
(PQ2) Donor socioeconomic status as a predictor of altered immune function and treatment response following hematopoietic cell transplantation for hematologic malignancy$357,337
R01 · FY2020 · CA
Treatment Modifications, Outcomes and Provider Decision Making in the Management of Subsequent Breast Cancers Among Survivors of Childhood Cancer$178,114
K08 · FY2020 · CA · contact PI
(PQ2) Donor socioeconomic status as a predictor of altered immune function and treatment response following hematopoietic cell transplantation for hematologic malignancy$392,698
R01 · FY2019 · CA
Treatment Modifications, Outcomes and Provider Decision Making in the Management of Subsequent Breast Cancers Among Survivors of Childhood Cancer$178,115
K08 · FY2019 · CA · contact PI
Treatment Modifications, Outcomes and Provider Decision Making in the Management of Subsequent Breast Cancers Among Survivors of Childhood Cancer$179,555
K08 · FY2018 · CA · contact PI